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OBJECTIVES: Preventive therapy has been accepted as a
standard protocol to reduce morbidity and mortality
from tuberculosis in HIV-infected patients. Conventional
cost-effectiveness analyses attempt to assess superiority
of one therapy over another in terms of monetary benefit.
The present study tries to determine variables that are not
considered in conventional cost-effectiveness analyses but
which are likely to have significant impact on disease out-
come.
METHODS: Based on MEDLINE search, compilation
and analysis of cost-effectiveness analyses of preventive
therapy for tuberculosis in HIV-infected populations
from 1995 to 2001.
RESULTS: Standard preventive therapies employed are:
isoniazid daily for six months; rifampicin plus pyrazina-
mide twice weekly for two months; isoniazid plus
rifampicin daily for three months. Variables considered
were medical care costs, social costs and cost per QALY
saved, i.e., which can be measured in terms of monetary
benefit. Isoniazid has been considered the most cost-
effective option. Important variables not considered were
risk of resistance—primary (isoniazid resistance 16.67%,
rifampicin 6.67%) or secondary (isoniazid resistance
61.76%, rifampicin 70.59%)—to the same patient upon
diagnosis of active tuberculosis and/or to the community
exposed; morbidity from adverse drug reactions and drug
interactions with anti-retroviral drugs.
CONCLUSIONS: Indiscriminate prophylaxis can in-
crease the chances of primary and secondary resistance
and morbidity from adverse drug reactions and drug in-
teractions. Study models to include these variables in
conventional cost-effectiveness analyses are needed to as-
sess the actual benefit of preventive therapy.
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OBJECTIVE: This paper presents a model based on real-
option analysis for evaluation of R&D in the pharmaceu-
tical sector, both for start-up ventures as well as for big
conglomerates. The analysis will be illustrated by means of
a case study and shows the valuable contribution of real-
option analysis compared to conventional DCF-analysis.
METHODS: The key understanding is that R&D projects
can be seen as growth options. The growth-option frame-
work looks at pharmaceutical investment projects as a
sequence of options, which differs from a conventional
DCF-analysis by incorporating the possibility of stopping
the project when a subsequent phase is not valuable (aban-
don the option), and of continuing the project (exercise the
option) when it is valuable. Traditional valuation tech-
niques such as DCF-analysis fail to fairly evaluate innova-
tive companies because most of the value of R&D projects
is embedded in unexercised real options whose future
value is uncertain at this moment. If one considers a com-
pany as a portfolio of real options, one can value the
projects or the company based on an option model.
RESULTS: The case study illustrates that real-option
analysis typically results in a higher project value than
conventional DCF-analysis would reveal. Real-option
analysis better reflects the fundamental value of the
project or of the company, which cannot be captured by
DCF-analysis.
CONCLUSION: This paper presents a new methodology
for evaluating pharmaceutical R&D based on real-option
models. As such, the real-option framework is better in
explaining the recent stock price behavior of biotech and
pharmaceutical firms.
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OBJECTIVES: It is difficult to accurately assess the im-
pact of influenza on hospital admissions. Most influenza
admissions are not coded as such, since the reason for ad-
mission is usually an underlying condition exacerbated
by influenza. The difficulty of assessing the excess burden
is complicated by the nature of commonly associated
conditions such as pneumonia, heart failure, and respira-
tory disease, all of which exhibit similar seasonal varia-
tions in numbers of hospitalizations. The objective is to
remove the seasonal variation to estimate the fluctuations
attributed to influenza during epidemic periods.
METHODS: We used a structural time series model that
included a stochastic trend and a trigonometric seasonal
function. Dummy variables (1 during influenza epidemic,
otherwise 0) were used to capture the excess hospitaliza-
tions over and above those that occur due to typical sea-
sonal fluctuation. Weekly hospital data on pneumonia
and influenza, all other respiratory conditions, and con-
gestive heart failure were modeled for public hospitals in
England and Wales.
RESULTS: The models explained between 72% and
95% of the variation in hospital admissions for the rele-
vant diagnostic groups (except CHF, explained variance
43%). We found a one-week lag in two models reflecting
the time elapsed between diagnosis and admission. Mean
numbers of excess admissions over a 10-year period were:
high risk 17,857 (range 12,779–26,104); elderly 17,856
(10,869–28,966); adult 4,820 (3,175–7,453).
CONCLUSIONS: Estimation of the burden of excess
hospitalizations must take account of underlying sea-
sonal variations. Traditional methods of estimation, such
as comparing epidemic and non-epidemic periods, are of
limited value. Furthermore, because much of the excess
hospital burden of influenza can be hidden (admission
codes reflect underlying conditions or complications), it
is necessary to take into account the variations in a wide
range of conditions.
